30.09.2011 • News

Geron Appoints John Scarlett as CEO

Geron announced that its board has appointed John Scarlett as its Chief Executive Officer and to its board of directors.

Scarlett brings over 25 years of executive leadership experience in the pharmaceutical and biotechnology industry to Geron. Most recently, he served as President and Chief Executive Officer of Proteolix.

David Greenwood, who has served as interim CEO, President and CFO of Geron since February 2011, will remain in his role as President and CFO during a transition period to continue through the end of this year, reporting to Scarlett.

In connection with the transition, Greenwood has resigned from the company's board of directors.

From Lab to Market Challenge

Choose your favourite among the finalists

Vote Now: Germany's Most Promising Chemistry Start-ups

The "From Lab to Market Challenge" brings together the most promising founders from chemistry, materials science, and industrial biotechnology. Starting June 1st, you can cast your public vote for the finalists on CHEManager.com — before the award ceremony with €10,000 in prizes takes place on June 25th.

Article

Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.